Our Approach

Developing Meaningful New Therapies for Those Who Need Them Most

Our lead drug candidates — lasofoxifene and ATH-1105 — are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited.

Our Clinical Trials

Designed to evaluate the safety and efficacy of our product candidates to advance our mission to provide better care for people through our innovative research and product development

Latest News

January 9, 2026

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

December 18, 2025

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

November 6, 2025

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Stay up to date

Get the latest news and updates sent directly to your inbox.

Complete and submit the form below.

By clicking SUBMIT, you agree to the processing of your personal information as described in our Privacy Policy.